You are here: Industry Insights > BioCryst

News List

BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO (berotralstat) by Health Canada and Swissmedic firstwordpharma
August 26, 2021
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the new drug submission for ORLADEYO®(berotralstat) has been accepted for review by Health Canada for the prevention of recurrent attacks in patients with hereditary angioedema (HAE).
BioCryst announces $325m of funding from Royalty Pharma and Athyrium Capital Management pharmaceutical-business-review
December 11, 2020
BioCryst Pharmaceuticals, Royalty Pharma, and Athyrium Capital Management, announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO (berotralstat) in hereditary ...
MHRA allows HAE patients early access to berotralstat pharmatimes
November 04, 2020
Patients with hereditary angioedema (HAE) living in the UK will get early access to BioCryst's berotralstat before the drug is officially approved for this indication by the European Commission.
BioCryst begins proof of concept trial in PNH patients with oral Factor D inhibitor, BCX9930 pharmaceutical-business-review
March 10, 2020
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH).
BioCryst terminates merger agreement with Idera pharmaceutical-technology
July 12, 2018
US-based BioCryst Pharmaceuticals has terminated the merger agreement with Idera Pharmaceuticals after its stockholders voted against the proposed deal.